The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | 3-year update on the ELOQUENT-2 clinical trial of elotuzumab in multiple myeloma
Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the 3-year update presented at the American Society of Hematology (ASH) 2015 Annual Meeting, on the ELOQUENT-2 clinical trial of elotuzumab in combination with lenalidomide and dexamethasone in multiple myeloma. The study demonstrated a sustained progression-free survival (PFS) benefit to patients in the elotuzumab arm, when compared to placebo in relapsed/refractory myeloma.
